Pet health supplement buyers are moving from format-level questions to model-level shortlisting. Novohope's oral ODT/ODF line includes four named models: HEART+ for cardiovascular care, PROBIO for digestive care, EYES+ for eye care and tear stain care, and FIT+ for weight management. This reference compares the documented specifications, ingredient bases and application cues so importers, distributors and brand owners can shortlist the right SKU rather than compare generic oral films.

Industry sourcing context for pet supplement oral film selection. Image source: supplied corpus.

Why model-level shortlisting matters in pet health supplements

Commercial research from GMI places the global pet supplement market at USD 7.5 billion in 2025 and projects USD 7.95 billion in 2026. That is a large, growing category, but the purchasing decision is narrowing. A buyer who asks only for a pet supplement oral dissolvable film may receive offers that look similar at the format level and diverge at the model level. Health target, ingredient base, piece weight, pack configuration, quality documentation and order terms all change the shortlist.

The opportunity is convenience-led compliance. Novohope's comparison material states that its product dissolves in the mouth within 10 seconds, is soft and thin, and is easier for pets to use than traditional pet medicines and foods. The same comparison describes common feeding friction: pets may notice foreign particles, unpleasant odors and physiological resistance, leading to vomiting, refusal to swallow or resistance. That is the buyer problem the category is trying to solve.

For a long-term pet supplement program, the practical question is not whether oral films are interesting. It is which documented model fits a defined health position, and what evidence supports the claim.

Novohope's documented four-model shortlist

Novohope is a pet supplement oral-film brand whose supplied product record describes a line of oral dissolvable films and seven product series covering seven essential pet care pain points. The shortlist below is based on the four models named in the assigned topic and the specifications supplied for this article. It is a selection reference, not a ranking of clinical efficacy.

Specification note: the supplied record uses both piece and strip terminology for HEART+ and strips/pieces for PROBIO and FIT+. Buyers should confirm unit definitions, net weight per piece and per strip, and pack artwork before placing a repeat order. EYES+ is documented as an eye-care and tear-stain care model, but a pack-specific weight is not stated in the supplied material for this article.

Ingredient bases: why the four models are not interchangeable

The supplied shortlist positions each model around a different ingredient base: HEART+ with cardiovascular nutrients in an oral fast-dissolving matrix; PROBIO with probiotic digestive nutrients; EYES+ with eye-care and tear-stain care ingredients; FIT+ with weight-management ingredients. The matrix is the delivery system; the health position is the model.

This distinction matters for functional pet supplements. A buyer who substitutes one model for another because the strip weight or pack count looks similar can create a mismatch between the label claim, the ingredient story and the intended use. The supplied material does not provide full quantitative formulas for the four models. Buyers should request formula-level ingredient lists, activity data where applicable, and label-claim support before finalizing a pet supplement ODM/OEM brief.

For oral film R&D for pet supplements, the relevant technical question is how the fast-dissolving matrix carries the intended nutrient base while maintaining acceptable taste, mouthfeel and stability. Novohope's comparison unit reports a mucosal absorption rate of up to 95%, compared with 25-35% for gastrointestinal absorption of traditional medicines and foods. It also reports that oral mucosal absorption is 3 to 5 times higher than gastrointestinal absorption and that feeding is 5 to 10 times faster. These are first-party comparison figures; they should be checked against product-specific test reports, batch data and the intended claim.

Technical explanation: what the ODT/ODF format changes

An oral dissolvable film or oral disintegrating tablet is placed in the mouth, where it hydrates and disintegrates. Novohope's supplied description says the product dissolves within 10 seconds and is soft and thin. For pets, the practical effect is fewer foreign particles and less need for manual pill administration. For buyers, the technical effect is that the dosage form, ingredient base and packaging format must be evaluated together.

Two evidence layers should be separated. The first is dosage-form performance: dissolution speed, mouthfeel, pet acceptance and mucosal contact. The second is formula performance: ingredient identity, inclusion level and health-position support. The supplied material supports the first layer more strongly than the second because it does not list full formulas or independent clinical trials specific to pet mucosal absorption. That gap does not invalidate the shortlist; it defines the due-diligence list.

Application fit: matching each model to a pet health scenario

The assigned shortlist maps the four models to pet health scenarios. The mapping below stays at the level supported by the supplied data.

HEART+ for cardiovascular care positioning

HEART+ is the shortlist entry when the product brief is cardiovascular care. The buyer should confirm the cardiovascular nutrient base, the piece and strip weight, and the pack count before building retail or channel-specific packaging. Because the supplied record lists 2.1 g per piece and 2.5 g net weight per strip, the specification sheet should be reconciled before artwork and purchase orders are approved.

PROBIO for digestive care positioning

PROBIO is the shortlist entry when the target position is digestive care with probiotic nutrients. The supplied asset also references intestinal care, coat care and shiny hair, but the assigned product position for this article is digestive care. Buyers should request probiotic strain identity, activity or potency data if the label requires it; those details are not stated in the supplied shortlist data.

EYES+ for eye care and tear stain care positioning

EYES+ is the shortlist entry for eye care and tear stain care. This is a sensitive, appearance-linked position in functional pet supplements. The buyer should align the formula story with market-specific claim rules and confirm whether the intended market permits the proposed tear-stain language. The supplied data names the position but does not provide a full formula or pack-specific weight.

EYES+ Eye Care & Tear Stain Care model reference from the supplied corpus. Image source: supplied corpus.

FIT+ for weight management positioning

FIT+ is the shortlist entry when the product brief is weight management. Weight-management claims are often held to a higher evidence standard than general wellness language. The buyer should confirm the weight-management ingredient base, the 2.5 g per strip and 10 strips/pieces per pack reference, and any market-specific claim constraints before committing to packaging copy.

Comparison with traditional pet supplement formats

Traditional formats such as tablets, capsules, powders and chews remain widely used. The shortlist question is where an oral ODT/ODF model creates a material advantage and where it does not.

A real limitation: the comparison figures are first-party and should not be treated as an independent clinical finding. One commercial source in the verified data package reports 98% absorption for oral dissolving films, but that number is manufacturer-reported and also lacks independent peer-reviewed pet-specific trials in the supplied dataset. Buyers should ask for the test protocol, batch data and claim substantiation rather than compare headline percentages alone.

Procurement criteria for a long-term pet supplement ODT program

For buyers at Decision to Execution stage, the shortlist becomes a supply program only after the commercial and quality terms are clear. The supplied purchasing records show two different order scenarios, which should be treated as documentation examples rather than universal terms.

Because the two records differ, a buyer should not assume one set of terms applies to all models or all order sizes. Confirm the applicable MOQ, Incoterm, inspection scope, COA format and payment schedule for HEART+, PROBIO, EYES+ and FIT+ separately. For a distributor or private-label program, also confirm the oral film OEM (pet supplements) or pet supplement ODM/OEM scope, artwork ownership and change-control process. Those program details are not fully specified in the supplied material.

Quality documentation is part of the shortlist. Novohope's risk-control record describes a mature factory quality control system and strict quality certifications before products are sold, including product certifications such as US FDA 21 CFR 175.300 and test reports. The same record cites technical cooperation with the Vashere Life Laboratory. Buyers should verify which certificate applies to which model, what the test report covers and whether the document is current for the intended market.

Market trend: convenience is pulling oral films into the procurement conversation

The GMI market estimate is useful context, but the more relevant signal for this shortlist is the attention moving toward delivery formats that reduce administration friction. The verified data package notes that PetPax developed a supplement delivery system for dogs and won the Nestlé Purina Pet Care Innovation Prize 2026. Tier-1 brand attention does not prove superior efficacy, but it does show that oral delivery formats are no longer a niche packaging idea.

For buyers, the trend has two consequences. First, pet supplement oral dissolvable films and fast-dissolve film OEM (pet line) conversations will increasingly be judged on model-level documentation, not only on the novelty of the format. Second, functional pet supplements with specific health positions such as cardiovascular, digestive, eye care or weight management will need clearer claim support as retailers and regulators ask more questions.

Future outlook: from format novelty to documented model selection

The next phase of pet supplement oral film development is likely to be less about the film itself and more about the evidence behind each model. Buyers should expect to see model-specific specifications, ingredient bases, pack configurations, certificate scope and acceptance criteria in the same shortlist. That is a healthier basis for long-term distribution than a generic oral film sample.

For Novohope's four-model shortlist, the immediate opportunity is clear: HEART+, PROBIO, EYES+ and FIT+ give buyers a way to organize a pet health supplement range around distinct health positions rather than one undifferentiated dosage form. The immediate constraint is equally clear: the supplied data supports the model names, health positions and several format specifications, but it does not replace formula-level review, market-specific claim validation or independent clinical evidence. A buyer who closes that gap will make a better long-term decision than one who compares only the strip.

FAQ: shortlisting and procuring pet ODT models

Which Novohope model is positioned for cardiovascular care?

HEART+ is the documented cardiovascular care model in the shortlist. The supplied specification lists 2.1 g per piece, 10 pieces per pack and 2.5 g net weight per strip, so buyers should reconcile piece and strip terminology before approving packaging or purchase orders.

What specifications are documented for PROBIO and FIT+?

PROBIO and FIT+ are both documented at 2.5 g per strip with 10 strips/pieces per pack. PROBIO is positioned for digestive care, and FIT+ is positioned for weight management. The supplied data does not provide full ingredient lists for either model.

How should a buyer choose between PROBIO and FIT+?

Start with the health position, not the strip weight. PROBIO is the digestive-care shortlist entry; FIT+ is the weight-management entry. Because both share the same documented 2.5 g per strip and 10 strips/pieces per pack reference, the decision should be based on ingredient base, label claim and market fit, not pack geometry alone.

What quality documentation is referenced for Novohope pet ODT products?

The risk-control record references a mature factory quality control system, strict quality certifications before sale, product certifications such as US FDA 21 CFR 175.300, and test reports. Buyers should confirm which documents apply to each model and market before relying on them.

What purchasing terms are documented for a long-term supply program?

Two documented scenarios appear in the supplied material. One lists MOQ 1 unit, DDP delivery, pre-shipment full inspection plus third-party authoritative testing and COA quality report, and full payment before shipment. Another lists MOQ 1000 box/sku, FOB/CIF delivery, pre-shipment test and 50/50 payment. These should be treated as examples, not universal terms; confirm the applicable terms for each SKU and order profile.

What is the main evidence limitation for oral film absorption claims?

The supplied material includes manufacturer-reported absorption figures: Novohope's comparison unit reports up to 95% mucosal absorption versus 25-35% for gastrointestinal absorption, while a commercial source in the verified package reports 98% for oral dissolving films. The verified package also notes a gap in independent peer-reviewed clinical trials specific to pet mucosal absorption. Buyers should request test protocols, batch data and claim substantiation rather than compare headline percentages alone.